None listed
Conditions
Interventions
Dietary Supplement : - dietary supplement name: Anthocyanin Olygomer
- dose: 200 mg
- frequency: 2 tablets/day, 2 tablets/serving (total 4 tablets, 800 mg/day)
- period : 12 weeks
- take method: ora
Sponsors
Dong-A University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ? Over the age of 18 healthy adult. ? Feeling of irritation, pain, itching, if appealing vision and symptoms such as glare. ? Hyperaemia conjunctivae, cornea erosion (nei with scale), meibomian gland and irregularities on the eye surface If you don't seem organic or more of the opinion. ? Schirmer's test award if more than 500 mm has drawbacks. ? If (tear break up time) 10 seconds or less destruction nunmulmak. ? Contact lens wearers must stop wearing them for the past month to select them.
Exclusion criteria
Exclusion criteria: ? If the patient is unable to test due to mental retardation or other reasons, ? A patient who is judged by the medical staff to be unable to participate in the study due to other ophthalmic diseases. ? If you do not want to or cannot observe the progress of visiting a research institute as part of treatment. ? Patients who do not want to participate in the study. ? In the case of diseases that can confuse the risk or outcome of surgery, such as immunosuppression and connective tissue disease, ? A woman of childbearing age. ? Other than eye trauma, infection, and dry eye surface inflammatory diseases, and those with a history of eye surgery within the last 6 months are excluded. ? If you have a history of using ophthalmic cyclosporin, steroid preparations, and other dryness treatment drugs within the last 1 month, ? Those who take antihypertensive drugs such as antihistamine and beta blockers, diuretics, antidepressants (especially tricyclic antidepressants, Parkinson's treatment drugs, etc.) that can worsen dry eye cannot participate in this study. ? Excluding subjects with diseases that can worsen dry eye by increasing inflammation of the surface of the eye, such as Sjogren syndrome, rheumatoid arthritis, ankylosing spondylitis, and erythema lupus.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| side effect, GOT/GPT | — |
Secondary
| Measure | Time frame |
|---|---|
| side effect, GOT/GPT | — |
Countries
Korea, Republic of
Contacts
Public ContactEun-Kyung Kim
Dong-A University
Outcome results
None listed